JPET #181560 measured. We found that intracellular levels of ceramide and phospho-p38MAPK were elevated in alveolar neutrophils from ARDS patients. Our results demonstrate that activation of the nSMase/S1P pathway to induce p38 MAPK phosphorylation results in inhibition of neutrophil apoptosis, which may contribute to the development of ALI.
Introduction
Acute lung injury (ALI) and its more severe form, acute respiratory distress syndrome (ARDS), are characterized by overwhelming lung inflammation and increased microvascular permeability causing diffuse lung edema and mechanical dysfunction (Wheeler and Bernard, 2007) . ALI/ARDS contributes to a significant amount of mortality and morbidity in adult patients admitted to intensive care units (ICU) . Mortality remains high (approximately 40%), although recent data have shown a reduction in mortality since the implementation of lung protective ventilatory strategies (Zambon and Vincent, 2008) . So far, there is no specific pharmacological therapy that reduces mortality and management is exclusively expectant and supportive, reflecting the lack of understanding of the cellular and molecular mechanisms contributing to the pathogenesis of ALI. Nevertheless, accumulating evidence has indicated a consistent association between neutrophils and ALI in humans and animal models, and the propensity of neutrophils and their products to cause tissue injury in experimental systems, leading to the conclusion that neutrophils have an important causative role in ALI (Zemans et al., 2009 ).
Neutrophil depletion is protective in many animal models of ALI, and blocking the major neutrophil chemoattractant, interleukin (IL)-8, protects rabbits from ALI and death following severe acid aspiration (Folkesson et al., 1995) . Studies showed that This article has not been copyedited and formatted. The final version may differ from this version.
JPET Fast Forward. Published on July 1, 2011 as DOI: 10.1124/jpet.111.181560 at ASPET Journals on April 5, 2017 jpet.aspetjournals.org Downloaded from JPET #181560 bronchoalveolar lavage (BAL) fluids from patients with early ARDS delay neutrophil apoptosis in vitro (Matute-Bello et al., 2000) . The inhibitory effect of BAL fluids on neutrophil apoptosis is associated with various cytokines such as granulocyte/macrophage colony-stimulating factor (GM-CSF), granulocyte colony-stimulating factor (G-CSF), IL-8, and IL-2 (Aggarwal et al., 2000; Lesur et al., 2000) . These factors cause persistence of activated neutrophils in the lung and sustained lung inflammation, and consequently increased organ damage and dysfunction. However, little is known about the intracellular signaling pathways regulating neutrophil activity in ALI. Efforts directed toward understanding key mechanisms to improve the detection and treatment of ALI are in urgent need.
Sphingolipids have been recognized as signaling molecules involved in a number of important cellular functions (Hannun and Obeid, 2008) . Ceramide, generated from the hydrolysis of sphingomyelin by acid or neutral sphingomyelinase (aSMase or nSMase) or through de novo synthesis, acts as a second messenger for apoptotic signaling triggered by various stresses, including oxidative stress, acid and ionizing radiation, and extracellular stimuli such as proinflammatory cytokines and lipopolysaccharide (LPS) (Mathias et al., 1998) . A recent study showed that inhibition of aSMase improves pulmonary function through decrease of ceramide generation in a neonatal piglet model of surfactant deficiency-induced ALI (von Bismarck et al., This article has not been copyedited and formatted. The final version may differ from this version. . A further metabolite of ceramide, sphingosine-1-phosphate (S1P) generated through ceramidase and sphingosine kinase, has in contrast been implicated in protection from apoptosis (Hannun and Obeid, 2008) . A previous study showed that both spontaneous and anti-Fas-induced neutrophil apoptosis are antagonized by S1P via modulation of the p38 mitogen-activated protein kinase (MAPK) pathway (Chihab et al., 2003) . Moreover, a strategy to activate the antiapoptotic signaling of S1P targeting lung endothelial cells has been shown to prevent alveolar damage in a mouse emphysema model (Diab et al., 2010) . In addition, S1P mediates diverse biological functions including cell proliferation, angiogenesis, formation of adherence junctions, cell motility and migration, and lymphocyte trafficking, acting either intracellularly as a second messenger or extracellularly as a ligand for a family of five G protein-coupled receptors, termed S1P 1-5 (Strub et al., 2010) . Previous studies have indicated that S1P is capable of modulating vascular barrier integrity in ALI (McVerry and Garcia, 2005) , and the inhibition of sphingosine kinase attenuates lung inflammation in an asthmatic mouse model (Nishiuma et al., 2008) . However, the role of sphingolipids in regulating neutrophil apoptosis during ALI is unclear.
Previous reports have demonstrated that p38 MAPK is important in regulating neutrophil functions and is activated in response to many stimuli such as LPS and tumor necrosis factor-α (TNF-α) (Nick et al., 2002) . In addition, p38 MAPK has been This article has not been copyedited and formatted. The final version may differ from this version. implicated in the regulation of apoptosis in different kinds of cells (Chen et al., 2008) .
In the present study, we found that following LPS challenge, nSMase is induced to hydrolyze sphingomyelin into ceramide, which is further metabolized to S1P, leading to the inhibition of neutrophil apoptosis via the phosphorylation of p38 MAPK. We also showed that treatment of mice with nSMase inhibitor following LPS-induced lung injury improved mouse survival and decreased the severity of lung damage. The activation of intracellular sphingolipid pathway and p38 MAPK in alveolar neutrophils from ARDS patients was also observed.
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Materials and Methods
Patients. We enrolled three patients who were admitted to ICU because of respiratory failure caused by sepsis-induced ARDS, defined as the presence of the following standard criteria: 1) acute hypoxemic respiratory failure requiring mechanical ventilation; 2) diffuse bilateral alveolar infiltrates on the chest radiograph;
3) refractory hypoxemia with arterial partial pressure of oxygen/fraction of inspired oxygen (PaO 2 /FiO 2 ) < 200, regardless of positive end-expiratory pressure level; 4) pulmonary artery occlusion pressure of < 18 mm H 2 O or no clinical evidence for left atrial hypertension; and 5) recognized sepsis syndrome for the development of ARDS.
Sepsis was defined according to the published consensus guidelines (Levy et al., 2003) .
Patients were excluded if they were < 16 years of age, had refractory respiratory failure (PaO 2 < 60 mmHg with FiO 2 = 1.0), or had unstable hemodynamic status and lethal arrhythmia even under the use of high-dose vasopressor and antiarrhythmia drug. We also included three patients with cardiogenic lung edema who were intubated requiring mechanical ventilation and absence of lung or systemic inflammation as the control subjects. The protocols and procedures were approved by the institutional review board of the National Cheng Kung University Hospital. Written informed consent was obtained from all subjects or their relatives. No topical anesthetics were used before BAL. The fiberoptic bronchoscope was introduced without bronchial suctioning, except after BAL. Heart rate, blood pressure and arterial oxygen saturation were monitored throughout the procedure. The bronchoscope was wedged into the right middle lobe or lingular division in the patients with diffuse pulmonary infiltrates. Six aliquots (20 ml each) of sterile normal saline were instilled and the fluid was aspirated immediately after each instillation. The first retrieved BAL fluids, reflecting a bronchial sample, were discarded and the remaining BAL fluids were pooled in ice-cold tubes for study. BAL was filtered through 70-μm nylon cell-strainer filters (Falcon, Becton Dickinson, Franklin Lakes, NJ) to remove mucus and then centrifuged at 500 × g for 15 min at 4°C to obtain a pellet corresponding to BAL cells, which were resuspended in 1 ml of phosphate-buffered saline (PBS). BAL cells were fixed with 1% paraformaldehyde in PBS and kept at 4°C for immunostaining. The dose of Sph-24 was chosen based on our preliminary experiments. After 24 h, mice were killed by following the procedures as below. In survival experiments, mice were injected intraperitoneally with Sph-24 3 h after PBS or LPS instillation, or with LPS instillation alone. This procedure was repeated after 24 h and subsequently the 6 days survival rate was assessed.
Reagents and

Assays of Mouse Lung Injury. Mice were killed 24 h after PBS or LPS intranasal
instillation. Mice were anesthetized, the trachea was cannulated and BAL was performed twice with 1 ml PBS (pH 7.4). The recovered fluid was centrifuged and the supernatant was analyzed for protein concentration by Bio-Rad assay (Bio-Rad, Hercules, CA). Cell pellets were pooled, resuspended in PBS, and the number of viable cells was determined by trypan blue exclusion. Thereafter, the left lung was inflated and fixed with 4% paraformaldehyde for histologic evaluation. Triton X-100 in PBS. For measurement of S1P levels, isolated human neutrophils were incubated in 10% FBS-RPMI, with or without pretreatment with SKI-II (10 μM), and CHL (4 μM) 30 min before addition of LPS (500 ng/ml). At 24 h, cells were fixed with 1% paraformaldehyde in PBS and permeabilized with 0.01% Triton X-100 in PBS.
A series of antibodies were used as indicated, followed by FITC-conjugated goat anti-rabbit IgG, anti-mouse IgG, or anti-mouse IgM (Calbiochem, La Jolla, CA)
staining. Mouse anti-ceramide and anti-S1P, and rabbit anti-phospho-p38 MAPK were This article has not been copyedited and formatted. The final version may differ from this version.
JPET Fast Forward. Histopathology. Mouse left lungs were infused with 4% buffered paraformaldehyde, embedded in paraffin, sectioned at 5 μm thickness, and stained with hematoxylin and eosin.
Western Blot Analysis. Isolated human neutrophils were placed in 10% FBS-RPMI, and then Sph-24 (50 μM), SKI-II (10 μM), and CHL (4 μM) were added 30 min before LPS (500 ng/ml) treatment, or LPS treatment alone. After 24 h, cells were washed in cold PBS and then pelleted and lysed in a Triton X-100-based lysis buffer (1% Triton X-100, 150 mM NaCl, 10 mM Tris [pH 7.5], 5 mM EDTA, 5 mM NaN 3 , 10 mM NaF and 10 mM sodium pyrophosphate) with a protease inhibitor mix and a phosphatase inhibitor cocktail I (Sigma-Aldrich). The protein concentrations of the lysates were determined by Bio-Rad assay. Equal amounts of proteins were loaded in each lane of a 10% SDS-PAGE mini-gel and separated by electrophoresis. Thereafter, the proteins were electrotransferred (100 V, 90 min) to polyvinylidene difluoride membranes in a This article has not been copyedited and formatted. The final version may differ from this version.
JPET Fast Forward. Data with three or more groups were analyzed by one-way ANOVA, followed by Tukey test as a method of post hoc analysis. All tests were two-tailed and P < 0.05 was considered significant. Survival curves were compared using the Log Rank test. All data were analyzed using GraphPad Prism 5.0 (GraphPad Software, San Diego, CA).
This article has not been copyedited and formatted. The final version may differ from this version. To determine the role of sphingolipids in modulating neutrophil apoptosis, we used LPS, which has been recognized as a principal pathogenic component in ALI, in inhibiting spontaneous apoptosis of human peripheral blood neutrophils ( Fig. 1A and Supplemental Fig. 1A ). LPS-induced suppression of neutrophil apoptosis was also confirmed by blockade of caspase-3 activation (Supplemental Fig. 1B) . Based on the fact that neutrophils are terminally differentiated and short-lived cells not amenable to in vitro genetic manipulation, we used chemical inhibitors to test our hypothesis. We found that Sph-24 (nSMase inhibitor) and SKI-II (sphigosine kinase inhibitor), but not CHL (aSMase inhibitor), antagonized the anti-apoptotic effect of LPS (Fig. 1B) .
SKI-II, a potent and selective inhibitor of sphingosine kinase 1, has been shown to have a weak direct inhibitory effect on sphingosine kinases 2 (Ren et al., 2010) .
Sphingosine kinase 1 has been implicated in cell growth, survival, movement, and cytoskeletal rearrangement. In contrast, sphingosine kinase 2 has been shown to suppress cell growth and enhance apoptosis (Maceyka et al., 2005) . In this study, we suggest that SKI-II mainly inhibits sphingosine kinase 1 to antagonize LPS-induced suppression of neutrophil apoptosis by decreasing S1P levels in LPS-treated neutrophils (Supplemental Fig. 2 ). We also demonstrated that LPS stimulated SMase JPET #181560 activity, which was diminished by pretreatment with Sph-24 but not CHL (Fig. 1C) , indicating the involvement of nSMase but not aSMase activation. Likewise, SKI-II treatment did not cause any effect on nSMase activity (Fig. 1C) . Together, these results suggest that S1P generation through the activation of nSMase, but not aSMase, mediates the anti-apoptotic effect of LPS in neutrophils.
LPS-Induced Sphingolipid-Mediated Inhibition of Neutrophil Apoptosis
Occurs via Phosphorylation of p38 MAPK. We next investigated whether p38
MAPK is regulated by sphingolipids, leading to the inhibition of neutrophil apoptosis.
By Western blotting of neutrophil lysates, we found that LPS-induced p38 MAPK phosphorylation was inhibited by Sph-24 and SKI-II, but not CHL ( Fig. 2A and B) . In addition, pretreatment with p38 MAPK inhibitor SB203580 blocked the anti-apoptotic effect of LPS (Fig. 2C) . These results suggest that nSMase/S1P-mediated inhibition of neutrophil apoptosis occurs via p38 MAPK activation. protein and cell counts in BAL fluids compared with mice treated with LPS alone (Fig.   3A and B) . Similarly, mice treated with Sph-24 showed less distortion of alveolar architecture, fewer thickened and disrupted septa and less intraalveolar bleeding and neutrophil infiltration, as compared with mice treated with LPS alone (Fig. 3C) . To further determine whether the decrease in lung inflammation is caused by alveolar neutrophil apoptosis, we determined apoptotic levels in BAL cells from mice with or without Sph-24 treatment. The results demonstrated that cell apoptosis was increased in BAL fluids from Sph-24-treated mice compared with mice treated with LPS alone (Fig. 3D) . Furthermore, LPS-treated mice given Sph-24 had an improved survival as compared with mice treated with LPS alone (Fig. 3E ).
Increased Levels of Sphingolipids in Alveolar Neutrophils from ARDS Patients.
We then sought to correlate the extent of sphingolipid signaling in alveolar Because ceramide upregulation is a critical step in sphingolipid metabolism, we compared ceramide levels in alveolar neutrophils of ARDS patients with those of cardiogenic lung edema, in which the lung function impairment is not related to lung inflammation, as indicated by markedly lower alveolar neutrophil counts compared with those from ARDS patients (Fig. 4B) . Ceramide content was measured by immunocytochemistry (Cogolludo et al., 2009) . Using immunostaining and flow cytometry, results showed significantly higher ceremide levels in alveolar neutrophils from ARDS patients than those from cardiogenic lung edema patients ( Fig. 4A and B) .
A previous in vitro study showed that S1P may counteract neutrophil apoptosis via the p38 MAPK pathway (Chihab et al., 2003) . In the present study, we show by immunostaining and flow cytometry that alveolar neutrophils from ARDS patients had higher levels of phospho-p38 MAPK, as compared with those from cardiogenic lung edema patients ( Fig. 5A and B) . 
Discussion
Sphingolipid signaling through aSMase-dependent ceramide production has been previously shown to induce apoptosis of lung endothelial cells and epithelial cells in ALI (Goggel et al., 2004) . In contrast to induction of apoptosis in endothelial and epithelial cells, apoptosis of neutrophils is decreased during sepsis (Gilroy et al., 2004) . The current study demonstrates that suppression of pulmonary neutrophil apoptosis in ALI is, at least in part, mediated through the nSMase, ceramide, S1P, and p38 MAPK pathway (Fig. 6 ).
The important role of neutrophils in ALI has been demonstrated by previous studies in which the severity of lung injury is decreased when neutrophils are eliminated (Abraham et al., 2000) . Neutrophil apoptosis is critical for the resolution of inflammation, which appears to be inhibited in ALI. Proinflammatory cytokines such as IL-1β, TNF-α, IFN-γ, GM-CSF, and G-CSF or bacterial products such as LPS inhibit neutrophil apoptosis, while IL-10 counteracts this inhibition (Keel et al., 1997; Aggarwal et al., 2000; Lesur et al., 2000) . To unravel the molecular mechanisms responsible for the decreased neutrophil apoptosis, a previous study found that circulating neutrophils from patients with sepsis are profoundly suppressed through a mechanism that involves activation of NF-κB, with a concomitant reduction in the activity of caspase-9 and -3 and the maintenance of mitochondrial membrane potential (Taneja et al., 2004) . A recent report showed that impaired cytoplasmic accumulation of myeloid nuclear differentiation antigen contributes to delayed neutrophil apoptosis during sepsis (Fotouhi-Ardakani et al., 2010) . In this study, we
show that neutrophils in BAL fluids from patients with ARDS have increased levels of ceramide. Together with the in vitro studies using human neutrophils and in vivo mouse model, we suggest that the intracellular sphingolipids may play a role in regulating neutrophil apoptosis during the development of ALI.
Sphingolipids such as sphingomyelin, ceramide, and S1P are known to regulate various cell functions and physiological processes, including apoptosis, vascular permeability, innate and acquired immunity, and to contribute to a variety of lung diseases such as pulmonary edema, emphysema, cystic fibrosis, and pneumonia (Uhlig and Gulbins, 2008) . In ALI, the increased aSMase activity and ceramide content induce apoptosis of pulmonary endothelial cells and increase vascular permeability, leading to edema formation (Goggel et al., 2004; von Bismarck et al., 2008) . However, the studies in human airway epithelial, and cerebral endothelial and glial cells have shown that nSMase but not aSMase is activated to induce cell death by cigarette smoke and amyloid beta-peptide, respectively (Yang et al., 2004; Goldkorn and Filosto, 2010) . S1P is derived from ceramide through ceramidase and sphingosine kinase, and is recognized as a regulator of cell proliferation and survival, This article has not been copyedited and formatted. The final version may differ from this version. angiogenesis and endothelial barrier functions via different S1P receptor subtypes (Spiegel and Milstien, 2003) . In a murine model of LPS-induced ALI, S1P
significantly decreased pulmonary vascular leakage and inflammation (Peng et al., 2004) . S1P can also function inside the cell, independently of S1P receptors, acting as an intracellular second messenger (Strub et al., 2010) . In contrast to ceramide, S1P prevents cells from undergoing apoptosis (Chihab et al., 2003; Hannun and Obeid, 2008) . In this study, we found that LPS increased nSMase activity, and pretreatment of nSMase inhibitor Sph-24 and sphingosine kinase inhibitor SKI-II antagonized the anti-apoptotic effect of LPS on neutrophils. Of note, treatment of Sph-24 appeared to be more effective in preventing the inhibition of neutrophil apoptosis by LPS as compared with SKI-II. Sph-24 is a selective and irreversible nSMase inhibitor (Delgado et al., 2006) . Similarly, SKI-II acts as a potent and selective inhibitor of sphingosine kinase 1 with no inhibition of protein kinase C-α, p42-MAPK/ERK2, or phosphatidylinositol 3-kinase (French et al., 2003) . However, a recent study has shown that SKI-II has a weak direct inhibitory effect on sphingosine kinase 1 and 2 activities in vitro in addition to triggering a lysosomal degradation of sphingosine kinase 1 (Ren et al., 2010) . As we mentioned previously, sphingosine kinase 1 is related to cell growth and survival, whereas sphingosine kinase 2 has been shown to suppress cell growth and enhance apoptosis. Based on the opposite effects of sphingosine kinase 1 and 2 on regulation of cell apoptosis, we reasonably propose that the efficacy of SKI-II on antagonizing LPS-induced suppression of neutrophil apoptosis may be slightly compromised. Of interest, aSMase inhibitor CHL had no effect on regulation of neutrophil apoptosis in response to LPS stimulation. CHL has been frequently used as a selective aSMase inhibitor. This compound induces proteolytic degradation of aSMase by interfering with the binding of the enzyme to the membranes of acidic vesicles and thereby rendering it susceptible to proteolytic cleavage by lysosomal proteases (Verdurmen et al., 2010) . Taken together, we suggest that delayed neutrophil apoptosis is mediated by S1P, which is derived from ceramide generated through the activation of nSMase but not aSMase. Furthermore, in vivo data are in line with these findings in an LPS-induced lung injury model as we observed decreased severity of ALI and increased survival by treatment with nSMase inhibitor. In this study, we used nSMase inhibitor Sph-24 for ALI treatment based on our in vitro findings, in which nSMase appeared to be more important in regulating neutrophil activation than aSMase, nevertheless, aSMase has been demonstrated to be more crucial in maintaining the alveolar-capillary barrier (Goggel et al., 2004) , and based on the previous report that S1P has protective effects in LPS-induced ALI through enhancement of endothelial vascular integrity (Peng et al., 2004) shock-induced lung injury in a rat model of trauma/hemorrhagic shock through suppression of neutrophil activation (Lee et al., 2004) .
Moreover, S1P has been linked to regulation of inflammatory responses as S1P might suppress IL-2-induced or T cell related inflammatory responses. However, S1P
has also been implicated in formation of adherence junctions, proliferation, survival, angiogenesis, and the trafficking of immune cells (Strub et al., 2010) . In this study, we suggest that S1P could be produced to prevent neutrophil from undergoing apoptosis in response to external stimuli, leading to sustained inflammation. Nevertheless, FTY720, a synthetic S1P ligand, acts as an immunosuppressive agent in which the mechanism involves the action of phosphorylated FTY720 in lymphoid tissues in not only activating S1P receptors but also down-regulating them. As a result, lymphocytes lose their responsiveness to S1P, blocking their egress from thymus or lymph nodes (Sensken et al., 2009) . FTY720 has been shown to protect from LPS-induced ALI in a murine model (Peng et al., 2004) . However, the protective effect of FTY720 is produced by endothelial cell barrier enhancement through the ligation of S1P 1 receptors, but not by immunosuppression. So far, its role in regulation of neutrophil activation and apoptosis remains unclear. In addition, the use of adrenocorticotropic hormone as an ARDS treatment (Steinberg et al., 2006) , because of its systemic effect on immunosuppression and a possible increase in infection rate and mortality, may not be ideal.
Activation of p38 MAPK has been shown to be involved in spontaneous neutrophil apoptosis (Chihab et al., 2003) . In contrast, other studies have indicated that p38
MAPK signaling contributes to the survival of mouse and human neutrophils (Alvarado-Kristensson et al., 2001) . In animal studies, treatment with p38 MAPK inhibitor before or during LPS-induced lung inflammation has been shown to result in significant decreases in the release of cytokines and chemokines and accumulation of neutrophils in the airspaces (Nick et al., 2002) . However, another study showed that inhibition of p38 MAPK did not decrease neutrophil accumulation in the lung or the development of ALI in the murine model of hemorrhage or endotoxemia (Arcaroli et al., 2001) . In our study, we found increased expression of phospho-p38 MAPK in Sph-24 group). *, P < 0.05. **, P < 0.01. ***, P < 0.001. Fig. 4 . Levels of sphingolipids in alveolar neutrophils of ARDS patients. A, the levels of ceramide (green) in alveolar neutrophils of patients with ARDS or cardiogenic lung edema were determined using immunostaining and co-stained with PI for nuclei (red), followed by flow cytometry. B, the averaged percentages of ceramide positive neutrophils determined by flow cytometry (black bar) and neutrophil counts (white bar) in BAL from patients with ARDS and cardiogenic lung edema are shown (n = 3 per group). Data are shown as means ± S.E.M. **, P < 0.01. ***, P < 0.001. 
